

NAACCR

# A&P

Please submit all questions concerning the webinar content through the Q&A panel.

If you have participants watching this webinar at your site, please collect their names and emails.


We will be distributing a Q&A document in about one week. This document will fully answer questions asked during the webinar and will contain any corrections that we may discover after the webinar.


2















# Intraperitoneal vs Retroperitoneal

- Intraperitoneal
  - Organ total covered and supported by peritoneum
    - Ovary
    - Liver
    - Transverse colon
    - ...
- Retroperitoneal
  - Anterior surface is covered by peritoneum
    - · Aorta. IVC
    - Kidney
    - · Adrenal glands
    - ...




NAACCR

9

# Primary Peritoneal

- Ovaries are not involved or only surface implants
  - Ovarian implants are typically less than 5mm
- Prognosis and treatment is similar to patients with papillary serous carcinoma of the ovary.
- These cases typically present with stage III or IV disease.



NAACCR

### Assigning Primary Site

after live presentation

- 1. Go with physician/surgeon/pathologist statement of primary site
- 2. Go with SEER rule for assigning primary site
  - See page 105 of the SEER Program and Staging Manual (Note 15) for additional instructions
- Involvement of peritoneal mets (i.e. peritoneal surface of fallopian tubes) is not a factor when assigning primary sites.

NAACCR

11

# SEER Coding Instruction (pg 105)

looking for a primary

tumor, not for mets


- When the choice is between ovary, fallopian tube, or primary peritoneal **without designation of the site of origin**, any indication of fallopian tube involvement indicates the primary tumor is a tubal
- Fallopian tube primary carcinomas can be confirmed by reviewing the fallopian tube sections as described on the pathology report to document the presence of either serous tubal intraepithelial carcinoma (STIC) and/or tubal mucosal invasive serous carcinoma.

 In the absence of fallopian tube involvement, refer to the histology and look at the treatment plans for the patient.

• If all else fails, assign C579 as a last resort. For additional information, see the CAP GYN protocol, Table 1: Criteria for assignment of primary site in tubo-ovarian serous carcinomas.

different Schema

NAACCR



# **Primary Site Codes**

- Ovary SchemaC56.9
- Fallopian Tube
  - C57.0
- Primary Peritoneal Carcinoma
  - C481, C482, C488

- Adnexa Uterine Other
  - C571-C574
- Genital Female Other
  - C55.7 Other specified parts of female genital organs
  - C57.8 Overlapping lesion of genital organ's
    - Tubo-Ovarian
    - Utero-Ovarian
  - C57.9
    - Female genital tract NOS

NAACCR

# Solid Tumor Rules-2024 Update

- Other Chapter
  - Table 13: Ovary Histologies
  - Table 15: Fallopian Tube Histologies

NAACCR

15

### Multiple Primary Rules

- M9 Bilateral epithelial tumors (8000-8799) of the ovary within 60 days are a single primary.
  - Note 1: Tumors must be same histology or be an NOS and subtype/variant (are on the same row in Table 13).
  - Note 2: Same row means the tumors are:
    - The same histology (same four-digit ICD-O code) OR
    - One is the preferred term (column 1) and the other is a synonym for the preferred term (column 2) OR
    - A NOS (column 1/column 2) and the other is a subtype/variant of that NOS (column 3)M10 Tumors on both sides (right and left) of a site listed in Table 1 are multiple primaries.

NAACCR

16

15

### Multiple Primary Rules

- Example:
  - Germ cell tumor, NOS 9064
  - Immature teratoma 9080
  - Dysgerminoma 9060
  - Yolk sac tumor, NOS 9071/3
  - Embryonal carcinoma 9070
  - Mixed germ cell tumor / mixed teratomayolk sac tumor 9085

NAACCR

17

### Histology Rules

- Rule H7
  - Code a combination code when there are multiple specific in situ histologies or when there is an NOS with multiple specific in situ histologies AND
  - The combination is listed in Table 2 in Equivalent Terms and Definitions, ICD-O and all updates OR
  - You receive a combination code from Ask A SEER Registrar

NAACCR

18

# Rule H7 Example

- Gyn malignancies with two or more of the following:
  - Clear cell
  - Endometrioid
  - Mucinous
  - Papillary
  - Serous
  - Squamous
  - Mixed cell adenocarcinoma 8323


NAACCR


19


# Additional Histology Note


• For ovarian primaries, code 9084/3 Teratoma with malignant transformation when a malignant (/3) histology arises in a benign teratoma.

NAACCR











Determining number of primaries and even primary site for ovarian/tubal neoplasms have become more complex based on a new understanding of these tumors, where they originate and how they spread. We are studying if the rules for these primaries should be changed and if so, what impact it may have on incidence rates and cancer surveillance.

-Lois Dickie, Senior Editor, Solid Tumor Rules

On April 23, 2024, Ask A SEER Registrar reached 40,000 submitted questions!!

#### Difficult Case 1

Rerecorded

- Review of case scenario 1
- How many primaries?

NAACCR

27

#### Difficult Case 2

Hysterectomy with bilat tubes and ovaries with bx's of other sites:

- Superficial invasion of posterior **endomyometrium** with high grade serous carcinoma
- **Rt ovary:** surface and parenchymal involvement of high-grade serous carcinoma largest focus 2.2 cm
- Lt ovary: surface and multinodular parenchymal involvement of high-grade serous carcinoma up to 1.8 cm
- Rt tube: serosal involvement of high-grade serous carcinoma
- Lt tube: Microscopic tumor in fimbriae
- Cervix: negative
- Peritoneal fluid: positive for high-grade carcinoma c/w gynecologic origin.
- Omentum excision: high grade carcinoma of gyn origin c/w hi grade serous carcinoma
   4.0 cm
- Small bowel mesentery bx: negative
- The synoptic states the site as posterior lower uterine segment.

WT-1 that is low may indicate an endometrial primary

#### Difficult Case 3

Bilateral salpingo-oopherectomy for menometrorrhagia:

- High grade serous carcinoma of the ovary. Carcinoma involves fallopian tubes and other ovary.
- Tumor site: ovary, laterality cannot be determined. Ovarian surface involvement present.
- Path comment:
  - Due to a larger amount of tumor on one of the ovaries an ovarian primary is favored. There is definitive invasion. Tumor is present in one fallopian tube and psammoma body is also identified in remaining tube. Ovaries are submitted in fragmented state and therefore laterality cannot be determined.

NAACCR

29

### Difficult Case 4

Hysterectomy with bilat tubes and ovaries, omentectomy and peritoneal biopsies:

- **Rt ovary and tube**: high grade serous carcinoma with involvement of uterine serosa, tumor size 5.0 cm rt ovary
- Lt ovary and tube: high grade serous carcinoma. Negative It tube. Tumor size 11 cm It ovary.
- Pelvic and abdominal peritoneum biopsy: high grade serous carcinoma.
- Left colic gutter biopsy: high grade serous carcinoma.
- Omentectomy: high grade serous carcinoma.

Synoptic on path states bilat ovary capsules intact. Site bilateral ovaries. Ovarian surface involvement bilateral. Fallopian tube surface involvement present on rt. Largest extrapelvic focus is macroscopic. Peritoneal fluid involvement present.

NAACCR


### Difficult Case 5


Hysterectomy w/bilat tubes and ovaries

- Rt ovary: negative
- Lt ovary: high grade serous ca 10 cm with no ovary surface involvement.
- Rt fallopian tube: serous tubal intraepithelial carcinoma
- Lt fallopian tube: no definite involvement by carcinoma
- Uterine corpus: negative

NAACCR

31






#### Fallopian tube Surgery Endometrium • A350 Unilateral (salpingo-) oophorectomy, unknown if hysterectomy done • A360 without Hysterectomy Cervix-• A370 with hysterectomy • A500 Bilateral (salpingo-) oophorectomy; unknown if hysterectomy done **Vagina** • A510 without hysterectomy • A520 with hysterectomy © 2012 Terese Winslow LLC U.S. Govt. has certain rights NAACCR

### Surgery

- A550 Unilateral/Bilateral (salpingo-)oophorectomy with Omentectomy, NOS; partial or total; unknown if hysterectomy done
  - A560 without hysterectomy
  - A570 with hysterectomy




NAACCR

35

# Surgery Codes


- Debulking; cytoreductive surgery A600
  - Debulking is a partial or total removal of the tumor mass and can involve the removal of multiple organ sites.
    - It may include removal of ovaries and/or the uterus (a hysterectomy).
    - The pathology report may or may not identify ovarian tissue.
    - A debulking is usually followed by another treatment modality such as chemotherapy.
  - A610 WITH colon (including appendix) and/or small intestine resection (not incidental)
  - A620 WITH partial resection of urinary tract (not incidental)
  - A630 Combination of A610 and A620

NAACCR



# Surgery Codes

- A700 Pelvic exenteration, NOS
- A710 Anterior exenteration
  - Includes bladder, distal ureters, and genital organs WITH their ligamentous attachments and pelvic lymph nodes.
- A720 Posterior exenteration
  - Includes rectum and rectosigmoid WITH ligamentous attachments and pelvic lymph nodes.
- A730 Total exenteration
  - Includes removal of all pelvic contents and pelvic lymph nodes.
- A740 Extended exenteration
  - Includes pelvic blood vessels or bony pelvis




NAACCR


37

# Systemic Therapy

- Neoadjuvant therapy
  - Poor surgical candidate or
  - Low likelihood of optimal cytoreduction
- Adjuvant therapy
  - IV platinum-based therapy
- Maintenance Therapy
  - May depend on BRCA status
  - Niraparib
  - Rucaparib
  - Olaparib
  - Bevacizumab



NAACCR





### SSDI - Residual Tumor Volume Post Cytoreduction

- Captures the amount of residual tumor volume grossly apparent after a cytoreduction procedure is completed.
- Source documents: **Operative report**, path report, discharge summary, chemo records
- Other names: Debulking, residual tumor volume

NAACCR

41

### SSDI - CA-125 Pretreatment Interpretation

- A tumor marker useful to monitor success of treatment and recurrence
- Record the interpretation of the highest value <u>prior</u>
   <u>to</u> treatment only by **blood or serum** CA-125
  - NOT on fluid from chest or abdominal cavity
- Source documents: Lab report, History, Clinician or Consultant notes or Path report

NAACCR

### SSDI - CA-125 Pretreatment Interpretation cont.

- Other names:
  - Cancer Antigen 125
  - CA 125 or CA125
  - Carbohydrate Antigen 125
  - Mucin 16 or MUC16

- Normal reference range:
  - ≤ 35 units per milliliter (U/MI); SI: ≤ 35 kiliUnits/Liter (KU/L)
  - May be reported as micrograms/milliliter (ug/mL)
  - Normal ranges may vary with patient's age and from lab to lab

43

NAACCR

43

### SSDI - CA-125 Codes

Code	Description
0	Negative/normal; within normal limits
1	Positive/elevated
2	Stated as borderline; undetermined whether positive or negative
7	Test ordered, results not in chart
8	Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code 8 will result in an edit error)
9	Not documented in medical record CA-125 not assessed or unknown if assessed

NAACCR

### SSDI - FIGO Stage

- There must be a statement about FIGO stage from the managing physician in order to code this data item
  - Do **not** code FIGO stage based on the pathology report
  - Do **not** code FIGO stage based only on T, N, M
  - If "FIGO" is not included with a stated stage, then do **not** assume it is a FIGO stage


NAACCR

45

### Pop Quiz 2

- Pathology Report notes that patient has:
  - HIGH-GRADE SEROUS CARCINOMA INVOLVING PARTIALLY CYSTIC OVARY and PATHOLOGIC STAGE: pt2b (FIGO IIB), pn0 noted on path report.
- The managing physician note states that the patient has a single ovarian malignancy that extends to other pelvic tissues, negative lymph nodes and no metastatic disease, Stage IIB and will refer to Radiation Oncology due to extension.
- When completing your SSDI what is your Figo Stage?
  - A. N/A
  - B. FIGO Stage IIB
  - C. Not documented in the patient record

NAACCR





# Summary Stage/Extent of Disease

- 3 Schema for Summary Stage and EOD
  - Ovary -> Schema ID 00551
  - Fallopian Tube -> Schema ID 00553
  - Primary Peritoneal Carcinoma -> 00552
- Single chapter for AJCC 8th edition
  - Chapter 55: Ovary, Fallopian Tube, Primary Peritoneal carcinoma.
    - See page 689


NAACCR

49


# Summary Stage 2018 - Ovary Notes

- Ascites, NOS is considered negative
- Lymph nodes with ITCs only are not counted as positive nodes for Summary Stage
- Peritoneal implants
  - Implants outside pelvis <u>must</u> be microscopically confirmed
  - If implants are mentioned, determine whether they are in the pelvis or in the abdomen and code appropriately to regional by direct extension (pelvis) or to distant (abdomen).
  - If not stated, code to distant.

NAACCR



	Code	Summ Stage 2018 Description	
	2	FIGO Stage IIA  - Extension to or implants on Adnexa, Fallopian tube, Uterus, FIGO Stage IIB  - Extension to or implants in Pelvis FIGO Stage II  - Confined to pelvis	NOS Fallopian tube Ovary Parametrium Cancer
	3	1100 Stage MA1	Vagina  2 2012 Tarese Window LLO U.S. Oset has center eights
	4	Regional by BOTH direct extension AND regional lymph node(involved	s)
ACCI	R <sup>)</sup>		



Code	Summary Stage 2018 Description	
7	FIGO Stage IVA - Pleural effusion w/ positive cytology FIGO Stage IVB - Extra-abdominal organs - Liver parenchymal - Spleen parenchymal - Transmural involvement of intestine Distant lymph nodes -> Inguinal	Cancer  Lymph nodes with cancer  Ovary  Ulterus  Bladder  Peritoneum

# **EOD Primary Tumor - Ovary Notes**

- When both the FIGO stage and Extension information is available - use the Extension information to assign code
- Code 050 for high-grade serous tubal intraepithelial carcinoma (STIC) (8441/2)
- Tumors in codes 100-250 with <u>malignant</u> ascites are coded to 300

NAACCR

55

# **EOD Primary Tumor - Ovary Notes**

- If there is involvement of the fallopian tube with no further evidence of extension, and the physician verifies this is an ovary primary, code 400.
  - 400 Extension to or implants on
    - Adnexa
    - Fallopian tube(s)
    - Uterus, NOS
    - FIGO Stage IIA

NAACCR

### **EOD Primary Tumor - Ovary Notes cont.**

- Both Extension to and/or Discontinuous mets to any of the <u>Pelvic</u> organs are included in code 450
  - 450-Extension to and/or discontinuous metastasis to pelvic sites (See Note 5); FIGO Stage IIB

Pelvic Organs		
Bladder and Bladder serosa	Rectosigmoid	
Broad ligament (mesovarium)	Rectum	
Cul de sac	Sigmoid colon	
Parametrium	Sigmoid mesentery	
Pelvic peritoneum	Ureter, pelvic	
Pelvic wall		

57

NAACCR

### **EOD Primary Tumor - Ovary Notes cont.**

 Both extension to and/or discontinuous mets to any of the <u>Abdominal</u> organs by way of seeding/implants are included in codes 600-750

Abdominal Organs			
Abdominal mesentery	Pancreas		
Diaphragm	Pericolic gutter		
Gallbladder	Peritoneum, NOS		
Intestine, large (except rectum, rectosigmoid and sigmoid colon)	Small intestine		
Kidneys	Spleen (capsular involvement only)		
Liver (peritoneal surface)	Stomach		
N Omentum (infracolic, NOS)	Ureters (outside pelvis)		


# EOD Primary Tumor - Ovary Notes cont.


- Implants mentioned unknown if pelvis or abdomen
   Code 750
- Direct extension and/or metastasis to the liver or splenic parenchyma are coded in EOD Mets
- Benign/borderline ovarian tumors Code 999

NAACCR

59

Code	Description
000	In situ, intraepithelial, noninvasive, preinvasive Low grade (LGSC) serous tubal intraepithelial carcinoma (STIC) (8441/2) Serous tubal intraepithelial carcinoma (STIC) (no grade) (8441/2)
050	High-grade serous tubal intraepithelial carcinoma (STIC) (8441/2)
100	Limited to one ovary (capsule intact) AND  No tumor on ovarian surface AND  No malignant cells in ascites or peritoneal washings  WITH or WITHOUT high-grade serous tubal intraepithelial carcinoma (STIC)  FIGO Stage IA
150	Limited to both ovaries (capsule(s) intact) AND  > No tumor on ovarian surface AND  > No malignant cells in ascites or peritoneal washings  FIGO Stage IB
200	Limited to one or both ovaries  > WITH surgical spill  FIGO Stage IC1
250	Limited to one or both ovaries  > WITH capsule ruptured before surgery OR > WITH tumor on ovarian surface  FIGO Stage IC2





# **EOD Regional Nodes - Ovary Notes**


- Code only regional nodes and Nodes, NOS in this field
- Inguinal Lymph nodes are <u>no longer</u> coded as regional lymph nodes - see EOD Mets
- Regional lymph nodes include bilateral and contralateral

NAACCR

63

Code	Description - EOD Regional Nodes Ovary
000	No lymph node involvement
050	ITC (< 0.2 mm)
300	LN metastasis - ≤ 10 mm
400	LN metastasis - >10 mm
500	LN metastasis - size unknown
800	Lymph node(s), NOS
999	Unknown; not stated; cannot be assessed; Death Certificate Only

Code	Description - EOD Mets Ovary
00	No distant metastasis or Unknown if distant metastasis
10	Pleural effusion with positive cytology
30	<ul><li>Distant LN's (Inguinal &amp; Distant LN's)</li><li>With or Without pleural effusion w/ positive cytology</li></ul>
50	Extra-abdominal organs (liver and spleen parenchymal, transmural involvement of intestine)
	Carcinomatosis (involvement of multiple parenchymal organs OR diffuse involvement of multiple non-abdominal organs)
	With or Without distant LN's OR pleural effusion w/ positive cytology



### Rules for Classification

- Ovarian cancer is primarily surgically/pathologically staged
- A patient presents with symptoms
  - Palpable pelvic mass and/or ascites
  - Bloating, pelvic or abdominal pain
- Ultrasound, CT, MRI
- Biopsy is rarely done due to risk of rupturing a cyst

NAACCR

67


67


# Tumor confined to one or both ovaries?


- Are one or both ovaries involved?
- Has the capsule ruptured?
- Are there malignant ascites or peritoneal washings?
- Is the ovarian surface free of metastatic tumors?




NAACCR















# Coming UP...

- Thyroid
  - Amy Bamburg, RHIA, CTR
  - Gillian Howell, MSc, PhD, CTR
- Life in a CoC Accredited Facility in 2024
  - Jennie Jones, MSHI-HA, CHDA, CTR
  - $\bullet \ \mathsf{Kim} \ \mathsf{Rodriguez}, \mathsf{CPH}, \mathsf{RHIT}, \mathsf{CTR}$

NAACCR

